Journal of Crohn's & colitis | 30 Sep 2016
EV Loftus, JF Colombel, BG Feagan, S Vermeire, WJ Sandborn, BE Sands, S Danese, GR D'Haens, A Kaser, R Panaccione, DT Rubin, I Shafran, M McAuliffe, A Kaviya, S Sankoh, R Mody, B Abhyankar and M Smyth
The GEMINI long-term safety (LTS) study is a continuing phase 3 trial investigating the safety and efficacy of vedolizumab, an α4β7 integrin antagonist for ulcerative colitis (UC) and Crohn’s disease. We provide an interim analysis of efficacy in patients with UC.
* Data courtesy of Altmetric.com